GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.
about
Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693.Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape.Initial testing (stage 1) of the Akt inhibitor GSK690693 by the pediatric preclinical testing program.Akt inhibitors in clinical development for the treatment of cancer.NF-κB and AKT signaling prevent DNA damage in transformed pre-B cells by suppressing RAG1/2 expression and activityp21-Activated kinase 1 is required for efficient tumor formation and progression in a Ras-mediated skin cancer model.Cell survival and metastasis regulation by Akt signaling in colorectal cancerHGF/Met and FOXM1 form a positive feedback loop and render pancreatic cancer cells resistance to Met inhibition and aggressive phenotypes.PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes.Integrin β3/Akt signaling contributes to platelet-induced hemangioendothelioma growth.Evaluation of 2-deoxy-2-[18F]fluoro-D-glucose- and 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer.The DNA Damage Response Regulates RAG1/2 Expression in Pre-B Cells through ATM-FOXO1 Signaling.AKT Hyperactivation and the Potential of AKT-Targeted Therapy in Diffuse Large B-Cell Lymphoma.The homeoprotein Dlx5 drives murine T-cell lymphomagenesis by directly transactivating Notch and upregulating Akt signaling.Effect of AKT inhibition on epithelial-mesenchymal transition and ZEB1-potentiated radiotherapy in nasopharyngeal carcinoma.DNA methylation in the central and efferent limbs of the chemo reflex requires carotid body neural activity.Expanding primary cells from mucoepidermoid and other salivary gland neoplasms for genetic and chemosensitivity testing.
P2860
Q33626022-A2AAE960-0B29-4337-A070-89CC46DF6CF2Q33920097-10B5EDB1-192C-4036-B15E-DF527D2913BFQ34249719-4E04C796-8187-4C33-AF5E-075309F5C641Q35628576-B5EAD170-6590-43D8-852B-E38848552348Q36351111-FED361C5-FA43-4769-A565-1287236807DFQ36405845-9FE643EE-EBF3-48BA-8054-5EB3AACE6A4DQ36938826-24FBD173-ABBC-417C-A73C-93A323122AE1Q37176592-A81F4EDB-503C-481C-AE14-8848659EF595Q37727180-0FE9E41C-1112-4CC0-8133-D7BCBD861618Q38696359-37DFFE3D-3C84-4223-9D6A-F100C3B1E0FCQ39367887-60BFE38D-0787-43B4-B79E-EA3DBD12EF3FQ39455556-6EC2A3B0-C167-488E-860D-2CBC377FBB18Q40154948-D2B0D653-E736-492E-863F-68B2B4C6E321Q42314702-73CCEF8F-F019-43BA-9934-D97A9A14BE0DQ42927132-92DF1CF8-BCFD-4BBE-A28A-8FD6A6553D53Q46259726-706B7C80-B12A-4772-B238-F5D492B52B36Q50119043-2E9FAD8C-CCF6-4594-8624-A51CA931B8F8
P2860
GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
GSK690693 delays tumor onset a ...... dels expressing activated Akt.
@ast
GSK690693 delays tumor onset a ...... dels expressing activated Akt.
@en
type
label
GSK690693 delays tumor onset a ...... dels expressing activated Akt.
@ast
GSK690693 delays tumor onset a ...... dels expressing activated Akt.
@en
prefLabel
GSK690693 delays tumor onset a ...... dels expressing activated Akt.
@ast
GSK690693 delays tumor onset a ...... dels expressing activated Akt.
@en
P2093
P2860
P1476
GSK690693 delays tumor onset a ...... dels expressing activated Akt.
@en
P2093
Andres J Klein-Szanto
Deborah A Altomare
Joseph R Testa
Lili Zhang
Rakesh Kumar
P2860
P304
P356
10.1158/1078-0432.CCR-09-1026
P407
P577
2010-01-01T00:00:00Z